• Ahmed M. Soliman Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza. P. O. Box 12211, Cairo, Egypt


Cefotaxime, Biochemical, Hepatotoxicity, Nephrotoxicity, Rats


Objective: The present study was carried out to evaluate the adverse effects of cefotaxime at two different doses on some biochemical parameters in albino rats. Histopathological changes in liver and kidney induced by cefotaxime were also investigated.

Methods: Thirty rats were randomly divided into 3 equal groups; the first group was received distilled water and kept as a control. The second group was received cefotaxime (90 mg/kg b. wt), while the third group was received cefotaxime (180 mg/kg b. wt). Cefotaxime at different doses were injected intramuscularly (IM) twice daily at 12 h intervals for 7 consecutive days.

Results: The obtained results showed that, cefotaxime produced significant elevation in creatinine, urea, sodium, potassium, calcium concentrations and decrease concentrations of both glucose and total protein in the serum of treated rats. Also, cefotaxime caused an elevation in some biochemical parameters as (Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), total bilirubin, Cholesterol, Triglycerides and Low density lipoprotein-cholesterol (LDL-chol) and decrease in albumin, High density lipoprotein-cholesterol (HDL-chol) concentrations in serum of treated rats. Histopathological alterations were observed in liver and kidney.

Conclusions: It could be concluded that administration of cefotaxime induced some adverse effects on biochemical parameters as well as histopathological changes in liver and kidney.



Download data is not yet available.


Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev Infect Dis 1982;4 Suppl:379-91.

Esmieu F, Guibert J, Rosenkilde HC, Ho I, Le Go A. Pharmacokinetics of cefotaxime in normal human volunteers. J Antimicrob Chemother 1980;6 Suppl A:83–92.

Neu HC. The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics. Ann Rev Pharmacol Toxicol 1982;22:599-642.

Kalager T, Digranes A, Bakke K, Hellum KB, Bergan T, Solberg C. Cefotaxime in serious infections: a clinical and pharmacokinetic study. J Antimicrob Chemother 1982;9:157-63.

Ings RM, Reeves DS, White LO, Bax RP, Bywater MJ, Holt HA. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. J Pharmacokinet Biopharm 1985;13:121-42.

Satyapal SU, Kadam VJ, Ghosh R. Hepatoprotective activity of Livobond, a polyherbal formulation against CCl4 induced hepatotoxicity in rats. Int J Pharm 2008;4:472-6.

Tietz NW. Fundamentals of clinical chemistry. 6th ed. Philadephia, PA: Saunders; 2000. p. 744-5, 788-9.

Heidland A, Horl WH, Schaefer RM, Teschner M, Weipert J, Heidbreder E. Role of alcohol in clinical nephrology. Klin Wochenschr 1985;63:948-58.

Newman DJ, Price CP. Renal function and nitrogen metabolites. In: Burits CA, Ashwood ER. Eds. Tietz Text Book of Clinical Chemistry. 3rded. WB Saunders Company, Philadelphia; 1999. p. 1204–70.

Patton CJ, Crouch SR. Enzymatic determination of urea according to the urease modified Berthelot reaction. Anal Chem 1977;49:464–9.

Young DS. Effects of drugs on clinical laboratory Tests. 3rded. AACC Press: Washington DC; 1990. p. 292–301.

Schmidt E, Schmidt FW. Determination of serum GOT and GPT. Enzyme Biol Clin 1963;3:1-5.

Jendrassik L, Grof P. Vereinfachte photo-metrische method zur bestimmung des bilirubins. Biochemische Zeitschrift B 1938;297:80-9.

Henry RJ. Clin Chem. 2nded. Harper and Row New York; 1974. p. 643-6.

Farell EC. Calcium Clin Chem. The C V Mosby Co. St Louis. Toronto. Princeton; 1984. p. 1051-5.

Deeg R, Ziegemohrm J. Enzymatic-colorimetric test (CHOD–PAP) in vitro diagnostic use only. J Clin Chem 1982;28:1574.

Stein EA, Myers GL. National cholesterol education program recommendations for triglycerides measurements executive summary. Clin Chem 1995;41:1421-6.

Valerie N. Effects of disease on clinical laboratory tests. In: Young DS, Friedman. American Association for Clinical Chemistry. 4th ed. AACC Press: Washington, DC; 2002. p. 682-3.

Harries ML. Carleton´s Histopathological Technique. 5thed. Oxford Univ. Press: New York, Toronto; 1989. p. 33-48.

Elsayed MG, Elkomy AA, Aboubakr MH. Hepatotoxicity evaluation in albino rats exposed to ceftriaxone. Asian J Pharm Biol Res 2011;1:145-50.

Feuer G, Balazs T, Farber T, Ilse R. Effect of cefazolin on aminotransferase activity in the rat. J Toxicol Environ Health 1981;7:593-606.

Gillian J, Gonard V, Dalmasso C, Palixc C. Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of 'free' bilirubin and erythrocyte bound bilirubin. J Antimicrob Chemother 1987;19:823-9.

Chen J, Ahmad J. Cefdinir-induced hepatotoxicity: potential hazards of inappropriate antibiotic use. J General Internal Med 2008;23:1914-6.

Peker E, Cagan E, Dogan M. Ceftriaxone-induced toxic hepatitis. World J Gastroenterol 2009;15:2669-71.

Panda NC. Kidney. In: Textbook of Biochemistry and Human Biology. 2nd ed. GP Talwar, LM Srivastava, KD Moudgil. Prentice-Hall of India. Private Ltd; 1989. p. 276-92.

Kohda Y, Matsunaga Y, Yonogi K, Kawai Y, Awaya A, Gemba M. Protective effect of serum thymic factor, on cephaloridine-induced nephrotoxicity in rats. Biol Pharm Bull 2005;28:2087-91.

Elsayed MG, Elkomy AA, Aboubakr MH. Evaluation of ceftriaxone nephrotoxicity in albino rats. Int J Agro Veterinary Medical Sci 2011;5:153-63.

Deki T, Matsuoka A, Marutani K, Nakagawa T, Masuda K, Matsuzawa T. Nephrotoxicity of cefpiromesulphate in rabbits-single and multiple intravenous administration. J Toxicol Sci 1990;15:173-200.

Kleinman LI, Lorenz JM. In: Clinical Chemistry: Theory, Analysis and Correlationâ€. (Kaplan LA and Pesce AJ. eds. CV Mosby Co: St. Louis; 1989.

Arise RO, Malomo SO. Effects of ivermectin and albendazole on some liver and kidney function indices in rats. Afr J Biochem Res 2009;3:190-7.

Takai A, Hirai S, Watanabe I, Hiraiwa T, Abe N, Omori M. General pharmacology of cefoperazone, a new cephalosporin antibiotic. Jpn J Antibiot 1980;33:994-1018.

Elsayed MG, Hassanin MR, Hafez MH, Elkomy AA, Mohamed A. Some pharmacodynamic and biochemical aspects of cefamandole. Dtsch Tierarztl Wochenschr 1997;104:481-7.

Kurebe M, Yokota M, Yuda Y, Sasaki H, Niizato T, Watanabe H. Toxicological studies of a new cephamycin, MT-141. II. Its subacute toxicity in rats. Jpn J Antibiot 1984;37:855-89.

Kato I, Ogawa M, Ueno M, Nishimura K, Sato K, Kii Y, et al. Toxicity study of cefmatilen hydrochloride hydrate (S-1090) Nephrotoxicity study in rabbits by single oral administration. J Toxicol Sci 2001;26:149-56.

Hayashi T, Maruden A, Irimura K, Kuwata M, Morita K. Nephrotoxicity of cefodizime sodium in rats-single and 14-day repeated intravenous administration. J Toxicol Sci 1988;13:285-327.

Morioka H, Yajima R, Inazu M, Kobayashi T, Sakaguchi T. Effect of cefodizime sodium on the kidney function in male rabbits-single and 7-day repeated intravenous administration. J Toxicol Sci 1988;13:329-60.



How to Cite

Soliman, A. M. “HEPATO-RENAL EFFECTS OF CEFOTAXIME IN ALBINO RATS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 11, Nov. 2015, pp. 312-5, https://journals.innovareacademics.in/index.php/ijpps/article/view/8498.



Original Article(s)